Type:
Educational Exhibit
Keywords:
Neuroradiology brain, CNS, Nuclear medicine, PET, MR, CT, Contrast agent-intravenous, Staging, Treatment effects, Multidisciplinary cancer care, Cancer, Neoplasia
Authors:
J. J. Delgado Moraleda, P. Sopena-Novales, S. Brugger, P. Oliván Sasot, A. M. Yepes Agudelo, A. ALEGRE DELGADO; Valencia/ES
DOI:
10.1594/ecr2018/C-0245
References
1.Bolcaen J,
Acou M,
Boterberg T,
Vanhove C,
De Vos F,
Van den Broecke C,
et al.
18F-PET and MRI FCho for the prediction of response in glioblastoma Patients ACCORDING TO the RANO criteria.
Nucl Med Commun.
2017 Mar; 38 (3): 242-9.
2.
Kwee SA,
Ko JP,
Jiang CS,
MR Watters,
MN Coel.
Solitary brain lesions at MR imaging Enhancing: evaluation With Fluorine 18 fluorocholine PET.
Radiology.
2007 Aug; 244 (2): 557-65.
3.
Mertens K,
J Bolcaen,
Ham H,
Deblaere K,
Van den Broecke C,
Boterberg T,
et al.
The optimal timing for brain imaging and other brain lesions Tumors With 18F-Labeled fluoromethylcholine: a dynamic positron emission tomography study.
Nucl Med Commun.
2012 Sep; 33 (9): 954-9.
4.
Treglia G,
Giovannini E,
Di Franco D,
Calcagni ML,
Rufini V,
Picchio M,
et al.
The role of positron emission tomography using carbon-11 and fluorine-18 in tumors other than choline prostate cancer: a systematic review.
Ann Nucl Med 2012 Jul; 26 (6):.
451-61.
5.
Hara T,
Kondo T,
Hara T,
Kosaka N.
Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas.
J Neurosurg.
2003 Sep; 99 (3): 474-9.